Prothena (NASDAQ:PRTA) Major Shareholder Buys 140,000 Shares of Company Stock

Prothena Corporation plc (NASDAQ:PRTA) major shareholder William Scully bought 140,000 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was purchased at an average price of $8.53 per share, with a total value of $1,194,200.00. Following the purchase, the insider directly owned 977,000 shares of the company’s stock, valued at $8,333,810. The trade was a 16.73% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Prothena Price Performance

Shares of PRTA stock traded down $0.22 on Tuesday, reaching $8.55. 231,682 shares of the stock were exchanged, compared to its average volume of 508,785. Prothena Corporation plc has a one year low of $7.73 and a one year high of $11.80. The stock has a market cap of $447.59 million, a PE ratio of -17.81, a P/E/G ratio of 2.96 and a beta of -0.20. The stock has a 50 day moving average price of $8.64 and a 200 day moving average price of $9.19.

Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). Prothena had a negative net margin of 80.68% and a negative return on equity of 16.45%. The company had revenue of $0.62 million during the quarter, compared to the consensus estimate of $9.58 million. On average, research analysts expect that Prothena Corporation plc will post 0.08 earnings per share for the current fiscal year.

Key Stories Impacting Prothena

Here are the key news stories impacting Prothena this week:

• Positive Sentiment: A Zacks report says the consensus price target implies about 120% upside for PRTA. It cautions that price targets alone are not especially reliable, while upward earnings-estimate revisions could be a more constructive near-term signal. Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High?
• Positive Sentiment: HC Wainwright maintained its Buy rating and $30 price target, a bullish view on the shares. Prothena analyst estimates and rating
• Negative Sentiment: HC Wainwright lowered its estimates for FY2027–FY2029 and FY2030, and increased its projected Q4 2026 loss to $0.44 per share from $0.38. These cuts point to weaker expected earnings in several future periods and temper the bullish target. It modestly raised its FY2026 estimate, however, to a loss of $0.44 per share from $0.47. Prothena analyst earnings estimates

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on PRTA shares. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Prothena in a report on Friday, July 24th. Wall Street Zen cut Prothena from a “buy” rating to a “hold” rating in a report on Saturday, July 25th. UBS Group reiterated a “buy” rating on shares of Prothena in a research report on Friday, July 24th. Finally, Weiss Ratings cut Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Prothena currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Institutional Investors Weigh In On Prothena

Several large investors have recently made changes to their positions in PRTA. Allspring Global Investments Holdings LLC acquired a new position in shares of Prothena during the 3rd quarter worth about $239,000. Chicago Partners Investment Group LLC grew its holdings in Prothena by 59.8% during the third quarter. Chicago Partners Investment Group LLC now owns 25,779 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 9,650 shares during the period. Pinnacle Associates Ltd. increased its position in Prothena by 6.2% during the third quarter. Pinnacle Associates Ltd. now owns 61,507 shares of the biotechnology company’s stock worth $515,000 after buying an additional 3,589 shares during the last quarter. Versant Capital Management Inc increased its position in Prothena by 179.1% during the third quarter. Versant Capital Management Inc now owns 5,704 shares of the biotechnology company’s stock worth $48,000 after buying an additional 3,660 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new stake in Prothena in the second quarter valued at approximately $404,000. Institutional investors and hedge funds own 97.08% of the company’s stock.

About Prothena

Prothena Corporation plc (NASDAQ: PRTA) is a clinical-stage biotechnology company focused on discovering and developing novel medicines for serious neurodegenerative and rare peripheral diseases. Its research is centered on disease-causing proteins, including amyloid-beta, alpha-synuclein and transthyretin, with the goal of creating antibody-based therapies that address underlying disease mechanisms. The company’s product pipeline has included birtamimab, an investigational antibody being developed for the treatment of AL amyloidosis, and prasinezumab, an investigational alpha-synuclein antibody being developed in collaboration with Roche for certain forms of Parkinson’s disease.